Renown Health Patients and Visitors

RENOWN NEWSROOM

Latest News Releases

Featured News

Careers

Awards & Accreditations

University of Nevada, Reno

Renown Health Foundation



Media Resources

Renown Public Relations Media Icon
Renown Health's Public Relations Team
news@renown.org

Renown Health's public relations team supports media partners in finding experts on diverse health care topics. In addition, we provide information and answer all questions regarding Renown. We look forward to working with you.

Read MoreMedia Resources
  • Media On Campus

    For patient confidentiality purposes, Renown Health policies require media to be escorted by the public relations staff at all times.

    PR staff will gladly make parking arrangements, notify the appropriate hospital staff and help you find your destination.

     

    Stand Ups/Live Broadcasts

    Media may conduct stand ups and live broadcasts on our campuses. In the interest of patient confidentiality and traffic flow, a staff member will help you find the best location for your story.

    We ask you to respect our obligation to protect our patients' well-being and legal right to privacy.

  • Patient Condition Inquiry

    We follow regulations of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) for all patients, including patients of public interest. HIPAA regulations specify which information may and may not be released without authorization from a patient.

    Patient privacy regulations allow us to only share patient condition information about patients that appear in our directory.

    Media inquiries require correct spelling of the patient's first and last name.

     

    Definitions of "Condition" used by Renown Health

    When describing a patient's condition, we can only release the following patient statuses:

    Good - Vital signs such as pulse, temperature and blood pressure are stable and within normal limits. Patient is conscious, comfortable and there are no complications.

    Fair - Vital signs are stable and within normal limits. Patient is conscious and alert although may be uncomfortable or in pain and may have minor complications.

    Serious - Vital signs may be unstable or outside normal limits. The patient is acutely ill or injured and may have major complications.

    Critical - Vital signs are unstable or outside normal limits. There are major complications.

    Note: "Stable" is not a condition.

Press Releases

Number of results found: 13
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page # 2 Navigate to next page Page 1 of 2
Skipped to 13 results found. Page 1 of 2
    • Wednesday, Sep 25, 2024

    Study From UNR Med and Renown in JAMA Network Open Highlights Gaps in Genetic Screening for Hereditary Breast and Ovarian Cancer

    Data demonstrates that a proactive approach to family history assessment and genetic screening will increase early detection of inherited risk. A new original investigation article published in JAMA Network Open, “Screening Familial Risk for Hereditary Breast and Ovarian Cancer,” by authors from University of Nevada, Reno School of Medicine, Renown Health and Helix for the Healthy Nevada Project® emphasizes the critical need to increase genetic screening in identifying individuals at increased risk of breast and ovarian cancer due to family history. This landmark study calls for enhanced awareness, the adoption of genetic screening practices, and, importantly, the direct screening of family history by individuals using a simple tool such as the FHS-7 questionnaire.   Breast and ovarian cancers remain leading causes of cancer-related deaths, with genetic factors playing a key role in up to 10% of cases. The study authors advocate for wider adoption of screening protocols, simple family risk questionnaires and education about the benefits of genetic testing, not only for patients but also their family members who may share similar genetic risks.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 36 women will die from breast cancer. Since 1990, breast cancer death rates have declined progressively due to advancements in screening, treatment and detection. Here in Washoe County, Nev., the age-adjusted mortality rate for 2020 (last update) is 21 deaths/100,000 females due to breast cancer, which is higher and worse than the national U.S. value of 19.6. Nevada ranks near the bottom in breast and cervical cancer deaths in women according to a recent Commonwealth Fund report. Across the U.S., approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime. The research underscores that individuals with a family history of breast and ovarian cancer have a higher likelihood of carrying genetic mutations in genes such as BRCA1 and BRCA2, which significantly elevate their cancer risk. However, many at-risk individuals remain unaware of their genetic predispositions due to limited screening practices.  Evidence suggests that “up to 80% of patients with a pathogenic or likely pathogenic (P/LP) variant in the BRCA1 and BRCA2 genes are unaware of their condition and subsequent risk for hereditary breast and ovarian cancer. Rare or less penetrant P/LP variants in genes such as PALB2, CHEK2 and ATM are even less likely to be detected. This is concerning because the lifetime risk for breast cancer exceeds 50% for women with P/LP variants in BRCA1/2 and 20% for women in P/LP variants in PALB2, CHEK2 and ATM (compared with a baseline risk of 12%).” The study also found that men with family history are just as likely to have pathogenic variants in BRCA1 and BRCA2 as women.  This is important because not only are men at increased risk of breast, prostate and other cancers, these risks are passed on to daughters, nieces and other members of the family through inheritance. Men are under-represented in the Healthy Nevada Project® and other similar population health studies. Daniel Kiser, MS, lead author of the study stated, "Our work shows that family history collected during routine medical care can be evaluated using simple criteria and used to identify patients with elevated risk for inherited cancers. Because there are a number of steps that can be taken to reduce risk, both for the patient and for their family members, following up with these patients has the potential to substantially reduce mortality and the incidence of cancer." “Prevention or early detection of disease is such an important part of healthcare,” says Bill Plauth, MD, MMM, CPE, Chief Medical Officer for Renown Health and Associate Dean for Clinical Affairs at the University of Nevada, Reno School of Medicine. “The Healthy Nevada Project® is leading the way in helping Renown Health physicians and clinicians assess family history risk of breast and ovarian cancer syndrome. This in turn, enables us to provide our at-risk patients the best available tools for prevention or to catch cancer at an earlier stage, which affords less aggressive treatment options with significantly improved survival.” The study found that routine genetic screening for individuals with a strong family history of these cancers could lead to more personalized and effective healthcare strategies, including preventative surgeries, increased surveillance, or early interventions. It also highlights the gap in awareness and access to genetic testing, particularly in underserved populations.  “One of the lessons from our work is the importance of assessing family history early and often in the healthcare journey of patients,” says Joseph Grzymski, PhD, Chief Genomics Officer of Renown Health, the Principal Investigator of the Healthy Nevada Project, and a faculty member in the Department of Internal Medicine at the University of Nevada, Reno School of Medicine. “We recommend that everyone get screened for CDC Tier 1 conditions but particularly, when family history indicates risks, genetic screening is a powerful tool for risk stratification.” Key Recommendations from the Study Authors Include: Increased Engagement of Patients with Physicians: People with a family history should discuss their history with their primary care physician or health care provider and request a genetic screening. This proactive approach to prevention will save lives. Increased Access to Genetic Testing: The need for more accessible and affordable testing options, like the no-cost screening provided by the Healthy Nevada Project®, particularly for those with a family history of breast or ovarian cancer. Increased Pre-Screening and Genetic Counseling: Providing patients with the necessary counseling to understand the implications of genetic mutations and guide their healthcare decisions. Pre-screening patients with either a personal or family history of cancer with one of several simple family history tools, such as the FHS-7 Questionnaire to determine whether they should be referred for genetic services would also help increase early identification and reduce costs.  As of January 2024, the Healthy Nevada Project® had notified 330 individuals with P/LP variants in BRCA1 or BRCA2 genes of their genetic risk, of a study population of more than 53,000 patients. The Healthy Nevada Project®, powered by Renown Health and University of Nevada, Reno School of Medicine, is one of the largest genomic studies in the United States. The genomic study is at no-cost for Nevadans and gives participants insight into different genetic traits, as well as results on their predisposition for three prevalent and serious health conditions known as the CDC Tier 1 conditions because of their significant potential to positively impact public health. Study authors include University of Nevada, Reno School of Medicine, (Daniel Kiser, MS; Gai Elhanhan, MD Iva Neveux, MS; William J. Metcalf, MS; Catherine McCarthy, MD; Leslie A. Greenberg, MD; Joseph J. Grzymski PhD); Helix, Inc. San Mateo, CA (Alexandre Bolze, PhD; Elizabeth T. Cirulli, PhD) and Renown Health, Reno (Savanna Grime, BA; Jamie M. Schnell Blitstein, APRN; William Plauth MD; Joseph J. Grzymski PhD.  For more information on the study, please visit JAMA Network. For a media interview, please contact Dr. Joe Grzymski at news@renown.org.  The Healthy Nevada Project®, led by Renown Institute for Health Innovation (Renown IHI) was launched in September 2016 as one of the first community-based population health studies in the United States. The study has already enrolled, consented and collected DNA from approximately 53,000 participants. Under the program, researchers and physicians are using genetics, environmental data and individual health information to empower providers with a targeted approach to personal health care and treatment, in turn improving the overall health and well-being of people in the local communities.  The University of Nevada, Reno School of Medicine, Nevada’s first public medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Since 1969, UNR Med has trained more than 3,900 students, residents, and fellows. UNR Med continues to improve the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national, and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu. Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,500 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. For more information, visit renown.org.

    Read More About Study From UNR Med and Renown in JAMA Network Open Highlights Gaps in Genetic Screening for Hereditary Breast and Ovarian Cancer

    • Thursday, Aug 08, 2024

    Groundbreaking Historic Milestone: Renown Pioneers Histosonics Edison® System Delivering Histotripsy for Non-Invasive Liver Tumor Treatment

    Renown’s Surgical Oncology team amongst the first to use HistoSonics' image guided histotripsy system to deliver non-invasive, personalized treatments for patients with liver tumors, thanks to a private donation. Watch this video to learn more about the technology.  Renown Health announced today that the first patients have received targeted liver tumor treatments through the Edison® System histotripsy technology, which uses focused ultrasound waves to noninvasively destroy a designated tissue or tumor in the liver. This revolutionary technology represents a significant advancement in providing leading-edge surgical care to patients. Renown joins the Cleveland Clinic, Mayo Clinic and Johns Hopkins in being amongst the first in the country to offer this revolutionary non-invasive clinical procedure. Surgical oncologists Christos A. Galanopoulos MD, MBA, MSc, FACS; Nicholas Manguso, MD; and Randy Zuckerman, MD of the William N. Pennington Cancer Institute at Renown Health, are amongst the first physicians in the world trained to perform the procedure which destroys both primary and metastatic liver tumors, including those that can’t otherwise be removed surgically. Renown’s multidisciplinary team includes surgical oncologists, radiologists, oncologists and nurses who collaborate to provide comprehensive care tailored to each patient’s needs.  “At Renown Health, we are constantly investing in our clinicians, essential services, and medical innovations to help keep care local,” said Brian Erling, MD, MBA, President & CEO for Renown Health. “We are grateful to a generous local donor, who provided us with a $1.4-million private donation to help purchase the equipment, training and to establish one of the few histotripsy programs in the U.S. at Renown. This non-invasive technology is a game changer in helping our liver surgeons and surgical oncologists to target and destroy malignant tissue in patients with either liver cancer or tumors that have spread to the liver from cancers based elsewhere in the body. This means people can now stay close to home and loved ones, and no longer need to leave Nevada for this type of advanced care.”  “As a surgeon, it’s rewarding to offer a procedure where we can precisely destroy liver tumors without using a scalpel or needles, enabling a patient’s quick recovery while avoiding certain complications common with other modalities,” says Dr. Christos Galanopoulos, Chair, Department of Surgery at Renown Health, and one of the oncology surgeons trained to perform the HistoSonics procedure. “Histotripsy uses focused ultrasound waves to mechanically destroy targeted tissue, offering a promising alternative to traditional surgical methods. This non-invasive approach reduces recovery time, minimizes complications, and improves patient outcomes. We look forward to the role this innovative technology will have in our treatment plans going forward.”  Revolutionary Technology “Histotripsy is a novel form of therapeutic ultrasound that precisely targets and liquefies tissue without damaging surrounding structures,” says Dr. Randy Zuckerman, surgical oncologist at Renown. “The system works by sending out focused ultrasound to targeted areas of tissue. The ultrasound energy creates pressure in the targeted tumor causing naturally existing gas bubbles to rapidly expand and collapse, helping break down and liquefy the targeted tissue. The entire process—from pre-treatment planning to real-time visualization—is assisted by advanced imaging technologies. We are confident that histotripsy will have a meaningful impact for patients suffering from unresectable liver disease, including liver tumors, and we are excited to share this advancement with our patients and community.”  The HistoSonics Edison® System and histotripsy procedure allows for: Precision and Accuracy: Histotripsy targets only the tumor cells, sparing adjacent healthy tissue, which is particularly advantageous in treating tumors located near critical structures.  Non-Invasiveness: As a completely non-invasive procedure, histotripsy eliminates the need for incisions, resulting in less pain and potentially faster recovery times for patients.  Reduced Risk of Complications: With no need for surgical intervention, patients face a lower risk of infection, bleeding, and other post-operative complications commonly seen in more invasive procedures. Renown’s Commitment to Innovation “The introduction of histotripsy underscores Renown Health’s dedication to staying at the forefront of medical advancements,” says Bill Plauth, MD, Chief Medical Officer for Renown Health and Associate Dean for Clinical Affairs at the University of Nevada, Reno School of Medicine. “By continually investing in the latest technologies and treatment modalities, we can ensure that patients receive the highest standard of care - right here in Reno.” Clinical trial results recently shared by the company showed that physicians were able to achieve a technical success rate of 95.5% in targeting and destroying malignant tissue in 44 patients with either liver cancer or tumors that had spread to the liver from cancers based elsewhere in the body.  Thanks to the Generosity of Our Community  "Through the generosity of our community, we are working to provide the best expertise, technology and programs for our patients,” said Greg Walaitis, Chief Development Officer, Renown Health Foundation. “As the only charitable, not-for-profit integrated academic healthcare organization in Reno, we appreciate that our community has helped us further our healing mission."  For more information about supporting innovative clinical care at Renown Health, visit www.renown.org/Foundation. To schedule a new patient appointment with the William N. Pennington Cancer Institute at Renown Health at 1155 Mill St in Reno, NV, call 775-982-4000. To schedule a patient for the HistoSonics procedure, call Dr. Christos Galanopoulos’ office (Renown Surgical Care) at 775-982-6270.  For media interviews, contact news@renown.org or 775-691-7308.  The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any specific disease or condition. Use of Edison System in kidney applications is limited by federal law to investigational use.     About HistoSonics HistoSonics is a privately held medical device company developing non-invasive platforms and proprietary sonic beam therapy utilizing the science of histotripsy, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquify unwanted tissue and tumors. The company is currently focused on commercializing their Edison System in the US and select global markets for liver treatment while expanding histotripsy applications into other organs like kidney, pancreas, and others. HistoSonics has offices in Ann Arbor, Michigan and Minneapolis, MN.  About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated health care network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,500 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. For more information, visit renown.org.

    Read More About Groundbreaking Historic Milestone: Renown Pioneers Histosonics Edison® System Delivering Histotripsy for Non-Invasive Liver Tumor Treatment

    • Wednesday, Mar 06, 2024

    Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

    Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

    Read More About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

    • Monday, Jan 29, 2024

    Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division

    Renown Health is pleased to announce that Kate A. Ward, Pharm.D., BCPS, has been promoted to serve as Vice President, Oncology for Renown Regional Medical Center.    Dr. Ward has over fourteen years of service to the organization, most recently as Director of Clinical Pharmacy responsible for the oversight of all clinical pharmacy activities at Renown Regional Medical Center, Renown South Meadows Medical Center, and Renown Rehabilitation Hospital. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown. Over the last decade at Renown, Dr. Ward has served as Pharmacy Clinical Manager, Pharmacy Clinical Coordinator and Clinical Pharmacist.   Dr. Ward will bring her pharmacy clinical service experience (including ICU, Outpatient Infusion, Pediatrics, Oncology and Emergency Services), Inpatient Care, Clinical Research, and Hospital Formulary Management, Electronic Medical Record Integration and Optimization to this important new role.   As a dyad partner with Max J. Coppes, MD, PhD, MBA, Director of the William N. Pennington Cancer Institute at Renown, she will bring her clinical, operational, regulatory, and administrative experience to lead the oncology division. Dr. Ward, Dr. Coppes and the dedicated team will advance Renown’s mission to expand care, prevention, screening, research, and education with the goal of establishing the first National Institutes of Health, NCI designated Cancer Center for our State.   “We are thrilled to welcome Dr. Ward as our new Vice President of Oncology. She brings a wealth of experience and a passion for advancing patient care. Dr. Ward will play a pivotal role in sharing the future our oncology division and furthering our commitment to providing exceptional care,” said Chris Nicholas, CEO of Renown Regional Medical Center.    As a licensed pharmacist, Dr. Ward holds a Doctor of Pharmacy degree from the University of Colorado, Health Sciences Center. The Pharm.D. is a professional degree like a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists.    Dr. Ward completed her residency at Stanford Hospital and Clinics. She graduated from the University of Nevada, Reno with her bachelor’s degree in Nutritional Sciences. Dr. Ward is active in several professional associations and currently serves as a Pharmacy Board member for HealthTrust; Vice Chair of the American Society of Health System Pharmacists® Council on Therapeutics; and Vice Chair for the Silver State Scripts Board for the State of Nevada. Dr. Ward was the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. To join the Renown Health team, visit renown.org/careers.

    Read More About Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division

    • Wednesday, Nov 01, 2023

    $5 Million Donation to Renown Health Foundation Will Increase Access to Breast Cancer Care in Northern Nevada

    Gift from Jeanne and Raymond Conrad will support development of the Conrad Breast Center in the new Specialty Care Center at Renown South Meadows Medical Center. Renown Health Foundation announced a $5 million gift from local philanthropists Jeanne and Raymond Conrad on Monday, Oct 30. This gift will establish the Conrad Breast Center at the William N. Pennington Cancer Institute at Renown. The center will be housed in the Specialty Care Center at Renown South Meadows Medical Center. The three-story, 121,000 square foot Specialty Care Center being built on the Renown South Meadows Medical Center campus will feature expanded laboratory and diagnostic services, a surgery center and expanded sterile processing department and more. The Conrad Breast Center is the latest addition to the services planned for the Specialty Care Center and will include imaging, infusion and surgery services along with a wellness center. “With a service area of over 100,000 square miles that serves approximately one million people, Renown sees individuals from all walks of life,” said Jeanne Conrad, philanthropist. “My husband Raymond and I share Renown’s vision for a healthy community and establishing advanced care options for even the most difficult-to-treat cancer cases. We all have been impacted by breast cancer in some way which is why we feel honored to create this legacy.” According to the National Cancer Institute, 12.9% of women born in the United States will develop breast cancer at some time during their lives (based on 2015–2017 data). Here in Nevada, the American Cancer Society estimates 2,620 new cases of breast cancer will be diagnosed in 2023 and that 440 Nevadans will die from breast cancer this year. “Renown Health’s mission to provide best-in-class care in our northern Nevada community and beyond is only possible with generous donors like Jeanne and Raymond Conrad,” said Brian Erling, MD, MBA, Renown Health President & CEO. “This gift establishing the Conrad Breast Center within the William N. Pennington Cancer Institute will positively impact lives in our community for years to come. Cancer does not discriminate and Renown strives to create care environments that cater to all individuals. Our goal is to save lives and ensure better outcomes while keeping families together with convenient care options.” During the formal announcement of the Conrad Breast Center on Monday, Oct. 30, Renown patient and breast cancer survivor, Carolyn Dragics, spoke about her experience receiving care at Renown. Carolyn emphasized that staying close to home was a crucial part of her care journey. To continue expanding regional cancer care options and keep locals close to home, Renown Medical Group recently welcomed two distinguished breast surgical oncologists, Colleen O'Kelly-Priddy, MD and Michelle K. Chu, MD to the team. As part of this expansion, Renown is assuming operations of Reno Surgical Advocates, a respected private practice in Reno. “Northern Nevada’s population continues to grow, and Renown is positioning itself to have the appropriate amount of cancer care providers available for everyone who may need it,” said Greg Walaitis, Renown Health Chief Development Officer. “As the region’s largest not-for-profit healthcare system, Renown works tirelessly to provide members of our community with advanced care. This establishing donation from the Conrad family will continue to build Renown’s vision for increasing cancer care options in our region.” “Every day I am inspired by not only the patients we care for who are fighting the good fight against cancer, but also by the donors like the Conrad family who have given us the opportunity to support our patients in their fight,” said Max Coppes, MD, PhD, MBA, Renown Health’s William N. Pennington Cancer Institute Director. The Conrad Breast Center is another step towards the William N. Pennington Cancer Institute’s ultimate goal for our community: establishing an NCI-designated Cancer Center in Reno.     About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health.

    Read More About $5 Million Donation to Renown Health Foundation Will Increase Access to Breast Cancer Care in Northern Nevada

    • Wednesday, Oct 04, 2023

    Saving More Lives; Renown Expands Breast Cancer Care, Adding Two Best-In-Class Breast Surgeons

    Renown Medical Group is thrilled to welcome two distinguished breast surgical oncologists, Colleen O'Kelly-Priddy, MD and Michelle K. Chu, MD to the team. These highly skilled breast surgeons will solely focus on providing breast care and therefore play a pivotal role in Renown Health’s William N. Pennington Cancer Institute’s commitment to provide subspecialized care to the people living in our community and beyond. Dr. Colleen O'Kelly-Priddy is a fellowship-trained, board-certified breast surgical oncologist with an impressive background in breast cancer surgery. Dr. Priddy was born at Washoe Medical Center (which later became Renown Regional Medical Center) and grew up in Susanville, CA before attending Stanford University for her undergraduate studies. She is a graduate of the University of Nevada, Reno School of Medicine. "I am thrilled to return to Reno to help increase access to world-class surgical breast cancer care,” said Dr. Priddy. “My focus is to provide exceptional care, particularly for young people with breast cancer. I am excited to continue my mission here in northern Nevada." Dr. Michelle K. Chu, a board-certified general surgeon, brings her extensive experience in advanced breast cancer treatment to the Renown team. Dr. Chu received her undergraduate degree from the University of Pennsylvania and her medical degree from Western Reserve School of Medicine in Cleveland, OH. Dr. Chu specializes in oncoplastic breast conserving surgery and nipple sparing mastectomies. "I believe in tailoring treatment options to each patient's unique needs,” Dr. Chu said. “Whether it's preserving the natural shape of the breast or supporting the 'Going Flat' movement, our team strives to provide the best possible outcome for every patient." The newest addition to the William N. Pennington Cancer Institute, Renown Breast Surgery Care provides comprehensive breast surgery care at 1500 E. 2nd Street in Reno, adjacent to the Renown Regional Medical Center campus. "Breast cancer accounts for approximately 20% of newly diagnosed cancer cases in Washoe County, with roughly 520 new cases annually, establishing it as the most prevalent cancer type within our community,” says Brian Erling, MD, MBA, President & CEO, Renown Health. “We are proud, as the community’s largest not-for-profit healthcare system, to invest in cancer prevention and early diagnoses, including mammography screening and genetic research. For those diagnosed with breast cancer, Renown now offers two superb breast surgeons specializing in breast preservation surgery, and a breast surgery center providing comprehensive, compassionate care. Our goal is to save women’s lives, save families and ensure better care and better outcomes. This is a major step forward for women’s healthcare and our community.” As part of this expansion, Renown is assuming operations of Reno Surgical Advocates, a respected private practice in Reno. "Access to expert breast cancer care close to home is crucial, and our dedicated team at Renown Breast Surgery Care will work tirelessly to provide the highest level of care to patients while working closely with our other cancer specialists," said Max Coppes, MD, PhD, MBA, Director, William N. Pennington Institute for Cancer. “With the exceptional expertise of Dr. Colleen O'Kelly-Priddy and Dr. Michelle K. Chu, coupled with our state-of-the-art facility; Renown Health is a true partner in the fight against breast cancer in northern Nevada.” "People are increasingly relocating to northern Nevada, and in fact, Washoe County experienced a 2.1% population growth from April 2020 to July 2022. Consequently, although northern Nevada does not exhibit an above-average cancer rate, we are observing a rise in cases at our facilities," said Dr. Lee Schwartzberg, MD, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute. "Renown Health is positioned to meet this growing demand, and we take pride in consistently adding nationally renowned healthcare providers to our team to save the lives of women in northern Nevada.     About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health.

    Read More About Saving More Lives; Renown Expands Breast Cancer Care, Adding Two Best-In-Class Breast Surgeons

    • Friday, Mar 24, 2023

    Freenome Adds Renown Health As Partner for The Sanderson Study

    Freenome, a privately held biotech company announced today that Renown Health has joined as a partner for the Sanderson Study, Freenome’s study of its multiomics platform, in combination with real-world data to detect multiple cancers. The study encompasses both traditional and real-world data to generate evidence of clinical validation for certain high- and elevated-risk populations while also refining the platform’s cancer classification and risk prediction models. In addition, the Sanderson Study will build the necessary infrastructure to bridge the gap between clinical research and day-to-day clinical impact. Freenome uses a multiomics platform that combines tumor and non-tumor signals with machine learning to detect cancer in its earliest stages using a standard blood draw. “We are delighted to partner with Freenome to launch this far-reaching trial which has transformative potential,” said Lee Schwartzberg, MD, medical oncology section chief and the principal investigator for the Sanderson Study at Renown. “Studying the impact of merging real-world information from patients with multiomics technology holds the promise of a truly personalized approach to early detection of cancer.” Renown Health has multiple clinical trials currently available to patients in northern Nevada across a variety of specialties, including oncology, cardiology, neurology, pediatrics, and pulmonology. Cancer is the second-leading cause of death in the Silver State, claiming the lives of more than 5,400 Nevadans each year. This number has increased since the last five-year plan estimates of 4,400 deaths per year.1 Promoting research to improve cancer prevention, detection, diagnosis and treatment is a key goal outlined in the Nevada Cancer Plan, 2021-2025, a framework developed by the Nevada Cancer Coalition in partnership with the Nevada Department of Health and Human Services. Access and participation in clinical trials is a key component of the plan, which, Renown says, makes participation in the Sanderson Study even more significant. “At the inception of the William N. Pennington Cancer Institute, we committed to not only provide the very best care possible to our community, but to also help improve outcomes through participation in research,” said Max Coppes, MD, PhD, MBA, cancer center director of the William N. Pennington Cancer Institute. “The research collaboration with Freenome has the potential to make a dream come true: Finding cancer early when it’s most treatable.” The Sanderson Study will enroll approximately 8,000 patients through Freenome’s clinical study partner network and numerous regional health systems across the United States. “Renown is committed to making a difference in the health and well-being of patients in communities across the state of Nevada, and that includes access to innovative research,” said Lance Baldo, MD, chief medical officer at Freenome. “The combination of real-world data and multiomics is poised to transform the landscape of early cancer detection.” Freenome’s clinical studies are named for employees’ loved ones who fought cancer. This study honors Tim Sanderson, the loving father of a Freenome engineer. For residents of Nevada interested in participating in the Sanderson Study, contact the William N. Pennington Cancer Institute clinical research coordinators at renown-crd@renown.org. Click here for more information on the Sanderson Study. About Freenome Freenome is a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a standard blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California. About Renown Health’s William N. Pennington Cancer Institute The William N. Pennington Cancer Research Institute provides comprehensive multidisciplinary cancer care for the northern Nevada community, helps educate the next generation of healthcare providers, and works to improve treatments and outcomes through active participation in research. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health.

    Read More About Freenome Adds Renown Health As Partner for The Sanderson Study

    • Monday, Jan 23, 2023

    Dr. Lee Schwartzberg Honored With 2023 Legends in Cancer Award

    Recognized as one of the world’s leading breast cancer experts as a 2023 Legends in Cancer Honoree Dr. Lee Schwartzberg, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute at Renown, was honored as the 2023 Legends in Cancer honoree at this year's Best of Breast conference for his contributions to the field of breast cancer. The conference took place on Jan. 21 and 22. Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 36 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates across the country, and here in Washoe County have declined progressively due to advancements in treatment, detection, and care. Each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 in men. Here in Washoe County, more than 21 deaths per 100,000 females are due to breast cancer, a significant decrease since 2012 when 24 deaths per 100,000 females were reported. Dr. Schwartzberg was selected for this award based on his unique and vast contributions to advancing science and patient care, including his major research interests such as therapeutic approaches to breast cancer, targeted therapies, and supportive care. The selection committee evaluates each candidates’ body of work — including contributions to the field of breast cancer in clinical research, patient care, mentoring and community service — before deciding on an honoree. “Dr. Schwartzberg is deserving of this honor. As a national expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is transforming cancer care and improving the lives of all of us in northern Nevada. As the most preferred cancer program in the region, we are working with the support of donors like The William N. Pennington Foundation to recruit additional oncology specialists and cancer science researchers to become the first National Cancer Institute-designated comprehensive cancer care center in Nevada," said Dr. Brian Erling, MBA, CEO of Renown Health. “The incredible care that comes from the William N. Pennington Cancer Institute is possible because of nationally recognized oncologists like Dr. Schwartzberg.” “Dr. Schwartzberg completed fellowship training in medical oncology and hematology at Memorial Sloan Kettering Cancer Center in New York, where he also served as Chief Medical Resident and was a founding member of the institutional ethics committee,” add Paul J. Hauptman, MD, dean of the University of Nevada, Reno School of Medicine and chief academic officer for Renown Health. “We are proud that he serves as a professor of clinical medicine at the University of Nevada, Reno School of Medicine. His research interests include supportive care, precision medicine and patient-reported outcomes in breast cancer and he has published over 300 peer-reviewed manuscripts, book chapters and monographs.” “It is an honor to work with Dr. Schwartzberg and his patients have the most incredible things to say about the care he provides.” said Dr. Max J Coppes, PhD, MBA, Director, William N. Pennington Cancer Institute, Renown Health. “He understands that his patients are going through one of the most challenging times in their lives. Dr. Schwartzberg brings decades of experience to our community, is a great listener, and treats everyone with compassion and dignity. We are so proud to have him at Renown.” The Best of Breast Conference is an innovative medical education program that gathers the world's leading breast cancer experts to discuss cases with high-risk characteristics, adjuvant and metastatic treatment advances, interdisciplinary care and survivorship and recurrence — all while incorporating data from the major oncologic annual meetings. Dr. Schwartzberg has been selected to chair Total Health’s spring oncology education retreat in Lake Tahoe on April 15 and 16. The event’s comprehensive agenda will allow attendees to engage with the latest research and strategies in cancer care while networking with colleagues from across the country in a peaceful setting. Additional conference information is available here. For women, breast exams using mammography after 40 years old is recommended. For those age 75 and older, a mammogram is recommended every year. Having regular mammograms can lower the risk of dying from breast cancer. Both 3-D digital mammography and whole breast ultrasounds are available at the Greenberg Breast Health Center at Renown and other locations across northern Nevada. The Affordable Care Act makes breast cancer screening and counseling free. All health plans must cover these benefits at no cost to you. Renown MyChart app users can self-schedule a mammogram appointment. To call to schedule, dial 775-982-8100. At the William N. Pennington Cancer Institute at Renown Health, patients receive innovative, personalized treatment to fight cancer while an experienced team provides the support and technology to maintain the highest quality of life. The Renown team’s clinical expertise and advanced treatment options blend evidence-based care with leading-edge research to improve cancer outcomes for every patient and family. For more information or a referral, visit renown.org/cancer. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®. About Total Health Total Health is a medical information company of planning experts who produce tailored content, courses, and conferences for oncology healthcare providers, virtual and in-person. Total Health believes knowledge is power. Its mission is to give oncology healthcare providers an educational experience that equips them with the latest strategies to improve clinical practice and treatment outcomes.

    Read More About Dr. Lee Schwartzberg Honored With 2023 Legends in Cancer Award

    • Wednesday, Aug 03, 2022

    Dr. Max Coppes to Lead William N. Pennington Institute

    Max Coppes, M.D., Ph.D., MBA who has served as Nell J. Redfield Chair of Pediatrics at the University of Nevada School of Medicine (UNR Med) and pediatrician-in-chief at Renown Children’s Hospital for the last six years has announced he is stepping down to lead Renown’s Pennington Cancer Institute on a full-time basis. Dr. Coppes will continue to serve as Professor of Pediatrics and Internal Medicine at UNR Med. “Our goal is to improve the health of Nevadans and reduce the burden of cancer,” said Thomas Graf, CEO of Renown Health. “Having Dr. Coppes as our clinical leader for the William N. Pennington Cancer Institute on a full-time basis reflects Renown and UNR Med’s commitment to increase access to cancer care, foster a deeper partnership with UNR Med on clinical trials, collaborate on cancer research opportunities, and enhance medical education and post-graduate training. We are thrilled to have Dr. Max leading this important effort.” Today’s announcement comes two weeks after the William N. Pennington Foundation announced a $15.5 million gift to the Renown Health Foundation to help establish the William N. Pennington Cancer Institute at Renown. Dr. Coppes, a pediatric oncologist by training, has experience in leading large-scale, nationally recognized academic cancer center teams in both the U.S. and Canada. Dr. Coppes came to Reno in 2014 from the British Columbia Cancer Agency in Vancouver, where he served as president with responsibility for six regional cancer centers and two cancer research centers. He was an attending physician at BC Children's Hospital and a professor of Medicine and Pediatrics at the University of British Columbia. During his career, Coppes served as senior vice president at Children's National Medical Center in Washington, D.C. and held positions at several prestigious facilities in the U.S. and Canada including The Hospital for Sick Children (SickKids) in Toronto, Georgetown University, The National Cancer Institute, and the Cleveland Clinic. Since 2016, Dr. Coppes has served in the joint leadership role as the Nell J. Redfield Chair of Pediatrics at UNR Med and pediatrician-in-chief at Renown Children's Hospital, a position made possible through generous philanthropic support from the Nell J. Redfield Foundation along with investments by Renown Health and the School of Medicine. In 2016, the Pennington Foundation recognized the need for enhanced care and expertise for pediatrics and donated $7.5 million to Renown Children’s Hospital to establish the William N. Pennington Fund for Advanced Pediatric Care. “As the Nell J. Redfield Chair of Pediatrics at the University of Nevada, Reno School of Medicine and pediatrician-in-chief at Renown Children's Hospital, Dr. Coppes blazed the trail for the integration of academic and clinical missions at UNR Med and Renown. He demonstrated visionary leadership and undoubtedly will bring the same energy and vision as the clinical leader for the William N. Pennington Cancer Institute,” said Melissa Piasecki, Acting Dean of UNR Med and Chief Academic Officer for Renown Health. “Dr. Max Coppes is an extraordinary leader. In the last six years he has done much to elevate the standard of pediatric care available in our community,” said Sy Johnson, President and Chief of Staff of Renown. “Thanks to Dr. Coppes’ leadership, the generosity of the Pennington gift and other donors, 100,000 area children now have access to pediatric specialists and contemporary healthcare services at the region’s only children’s hospital. Now, less than 3% of all pediatric patients and their families need to leave the area for specialty care. That is an incredible accomplishment.” Significant achievements made under Dr. Coppes leadership include: Advancing Renown Children’s Hospital, the only dedicated children’s hospital in northern Nevada, offering programs and services for families from a 100,000 square mile area, from Sacramento, CA to Salt Lake City, Utah. Renown Children’s provides the area’s only Children’s Emergency Room, Pediatric ICU (PICU), children’s imaging center and the largest neonatal ICU (NICU), a level III intensive care unit. Under his leadership, the following service lines were established; adolescent medicine, pediatric hematology/oncology, pediatric nephrology, pediatric infectious diseases, pediatric ophthalmology, pediatric orthopedic surgery, pediatric cleft and craniofacial surgery, pediatric urology, pediatric dentistry, and pediatric emergency medicine. Hiring and supporting a team of over 40 pediatric physician specialists. These clinicians provide 30,000 patient visits annually, offering an exceptional level of care to help families. As a testimony to the community’s confidence in the care provided, market share for pediatric services at Renown Health is now close to 90%. Renown’s membership in the Children’s Oncology Group (COG), which gives local pediatric cancer patients access to the world’s largest organization devoted exclusively to childhood cancer and most leading-edge treatments. Application to establish a 3-year accredited (by the Accreditation Council for Graduate Medical Education (ACGME) pediatric residency program in Reno. If approved in September 2022, Renown Health and UNR Med will start training four new pediatricians each year starting in July 2023. Successful application to the Nevada Governor's Office of Science, Innovation & Technology to receive financial support to fund a new Graduate Medical Education program. Renown Children’s Hospital was awarded $ 870,433 for the new pediatric residency program. New construction of an expanded Neonatal Intensive Care Unit (NICU) with increased capacity to 49 bassinets, an expanded Pediatric Intensive Care Unit (PICU) with increased capacity to 16 private patient and family rooms, and a new Renown Children's Hospital in-patient floor with increased capacity for 38 private patient and family rooms for a total capacity of 58 pediatric beds on Level 4 of Renown Regional Medical Center. In 2021, Dr. Coppes was named the Healthcare Hero Community Partner by Northern Nevada Business Magazine.

    Read More About Dr. Max Coppes to Lead William N. Pennington Institute

    • Wednesday, Jul 13, 2022

    Joining the Good Fight: Pennington Foundation Donates 15.5 Million Dollar Grant to Transform Cancer Care in Northern Nevada

    Generous gift will establish the William N. Pennington Cancer Institute at Renown Health. The William N. Pennington Foundation has announced a $15.5 million gift to the Renown Health Foundation to help establish the William N. Pennington Cancer Institute at Renown. This gift will help to bolster care and clinical expertise to improve the lives of people with cancer across northern Nevada. This is the largest gift Renown has ever received. This is the second major donation Renown Health has received from The William N. Pennington Foundation. In 2016, the Pennington Foundation recognized the need for enhanced care and expertise for pediatrics and donated $7.5 million to Renown Children’s Hospital to establish the William N. Pennington Fund for Advanced Pediatric Care. Through this gift, 100,000 area children now have access to pediatric specialists and contemporary healthcare services at the region’s only children’s hospital. Prior to 2016, about 30 percent of all pediatric patients had to leave northern Nevada to receive the specialty care they needed. Now, thanks to the Pennington Foundation’s support, Renown estimates that 97% of all pediatric patients and their families can receive both general and specialty pediatric care locally. Now, improving access to cancer care services in northern Nevada is the priority. According to the National Cancer Institute, approximately 39.5% Americans will be diagnosed with cancer at some point during their lifetimes (based on 2015–2017 data). Here in Nevada, the American Cancer Society estimates 16,390 new cases of cancer will be diagnosed in 2022 and that 5,730 Nevadans will die from cancer this year. The most frequent cancers seen include breast, prostate, lung and colo-rectal cancers. “The Pennington Foundation gift is so appreciated, as it honors a man who had a passion for improving lives and provides a legacy for the our current generation,” said Thomas R. Graf, M.D., FAAFP, Chief Executive Officer of Renown Health. Dr Graf also serves as Chief Clinical and Quality Officer at Renown, and Senior Associate Dean for Clinical Affairs for University of Nevada, Reno School of Medicine. “We are deeply grateful for this transformative gift. This gift will allow Renown to continue our mission of making a genuine difference in the health and well-being of people with cancer- their families, and the communities we serve.” The Renown Institute for Cancer will now be named the William N. Pennington Cancer Institute in honor of the man who was a gaming pioneer, businessperson, and philanthropist. In former publications, the late philanthropist, Bill Pennington said, “During my many years in business, I was fortunate to work with thousands of wonderful employees, all of them Nevadans. Their efforts helped create the William N. Pennington Foundation, and I hope the Foundation will, in turn, help future generations of Nevadans for many years to come.” The Pennington grant will focus on bolstering expert clinical care to address the many concerns that come with a cancer diagnosis and allow people to stay in northern Nevada instead of having travel hundreds of miles out of the area for specialty care. The Institute will be devoted to advancing cancer care, cancer screening, prevention, and cancer research, including the ability to offer the latest clinical trials. “Our goal is to offer our community comprehensive clinical services, basic, translational and clinical research, medical education to students and post-graduate training, and population health with community outreach to reduce the burden of cancer. Ultimately, the vision is to become accredited by the National Cancer Institute,” said Max J. Coppes, MD, PhD, MBA, Cancer Center Director. “We are incredibly thankful and grateful for the commitment and support of the William N. Pennington Foundation,” said Greg Walaitis, Renown Health Foundation’s Chief Development Officer. “We appreciate the Pennington Foundation’s belief in Renown’s charitable mission to build a healthier community, together. We thank them for Joining the Good Fight.”   Renown Health is the region’s largest locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The University of Nevada, Reno School of Medicine (UNR Med) and Renown Health affiliated in June of 2021 to establish Nevada’s first integrated health system with missions in education, patient care, and clinical research. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

    Read More About Joining the Good Fight: Pennington Foundation Donates 15.5 Million Dollar Grant to Transform Cancer Care in Northern Nevada

    • Wednesday, Jan 05, 2022

    Renown Children’s Hospital Joins The Children’s Oncology Group

    Dr. J. Martin Johnston, Renown Health's Chief of Hematology and Oncology. Renown now home to northern Nevada's only Children's Oncology Group institution, giving local pediatric cancer patients access to the most cutting-edge treatments. Renown Children's Hospital announced today that it is now a member of the Children's Oncology Group (COG), the world's largest organization devoted exclusively to childhood cancer. Membership in the COG allows Renown to enroll its youngest patients in the latest clinical trials, including ground-breaking treatments for many childhood cancers, studies to better understand these diseases, and trials focused around supportive care and survivorship. Renown is now enrolling pediatric patients in clinical trials through the COG. Through this process, many childhood cancer patients will be eligible to receive newly-developed therapies.  For example, some trials employ immunotherapeutic drugs in addition to conventional chemotherapy, in hopes that adding the immunotherapy results in better health outcomes for pediatric cancer patients. "As a pediatric intensivist by training, I understand how quickly advancements are made in pediatric medicine," said Tony Slonim, MD, DrPH, President & CEO of Renown Health. "As a member of the COG, pediatric oncology patients of Renown Children's Hospital now have access to the latest and most cutting-edge treatment options in addition to commonly prescribed treatments. I am proud of the highly-skilled caregivers at Renown who are constantly expanding their knowledge and contributing research to give our pediatric patients and their families hope for the future." "Until now, we have been able to offer treatments at Renown based on the current standard of care, which means the treatment is based on published trial results that may not reflect the latest research in the field," said Renown's Chief of Hematology/Oncology, J. Martin Johnston, MD. "Previously, a pediatric oncology patient could only enroll in a COG trial if the family had the capacity to temporarily relocate to the Bay Area or Salt Lake City, for example. Now, our patients will have the opportunity to enroll in these trials without the need to travel so far from home." "When faced with pediatric cancer, the last thing parents should worry about is traveling great lengths to receive the best in cancer care," said Larry Duncan, Vice President of Pediatrics and Surgery and Administrator, Renown Children's. "We are proud to now offer the most advanced childhood cancer treatment options here at Renown, close to home and convenient for area patients and their families. We always strive to see more patients beat cancer, and being part of the COG helps our expert team of pediatric oncologists implement innovative and new ways to make that happen." Carson City local Brenda Milligan's son, Austin, was 5 when he was diagnosed with leukemia and received treatment at Renown Children's Hospital. As an active participant in her now 10-year-old son's treatment plan, Brenda shares that she regularly sought out advice from COG providers across the country and is pleased that northern Nevadan parents of children being treated for leukemia can now take full advantage of the COG right at home. "The COG allows Renown's providers to have access to treatment plans that weren't available when Austin was receiving treatment," said Brenda. "It comforts me to know that not only can children receive cancer treatment right at home, but their parents can now elect for them to participate in trials and plans that are at the forefront of cancer treatment today." According to the COG, more than 90 percent of 14,000 U.S. children and adolescents diagnosed with cancer annually are cared for at COG member institutions. As a COG member institution, Renown joins over 200 institutions including Stanford, UCSF and Kaiser Permanente in this prestigious honor. The COG is made up of more than 9,000 experts worldwide and has nearly 100 active clinical-translational trials running at once. Research from the COG has drastically transformed children's cancer outcomes. Just 50 years ago, pediatric cancer was thought to be untreatable; while today, it has a combined five-year survival rate of 80 percent. "The key to ending childhood cancer is through extensive scientific research and clinical trials," said Max Coppes, Cancer Center Director at Renown Institute for Cancer. "As a COG member institution, our doctors will have the opportunity to collaborate with other pediatric oncologists around the world who share a common goal—to cure all children of cancer. At Renown, we are proud to be at the forefront of life-saving research and treatments for pediatric oncology patients throughout our region." "We are also grateful to the William N. Pennington Foundation for its support in establishing the William N. Pennington Fund for Advance Pediatric Care in 2016, which allowed us to hire more than 15 specialized pediatricians, including in oncology/hematology, which was crucial to our application for COG membership." About Renown Children's Hospital Renown Children's Hospital is the only dedicated children's hospital in northern Nevada, and offers a variety of programs and services designed specifically to care for families in our community. It has the region's only pediatric ER and ICU. Renown Children's Hospital is not-for-profit and relies on philanthropic support. Visit renown.org/give to support Renown Children's Hospital. For more information on programs and services, visit renown.org/children.

    Read More About Renown Children’s Hospital Joins The Children’s Oncology Group

    • Monday, Mar 08, 2021

    Awareness Saves Lives: Renown Goes Blue for Colorectal Cancer Awareness Month

    After a year of possibly delayed colorectal cancer screenings due to theCOVID-19 pandemic, it’s more important than ever to raise awareness for colorectal cancer. March is National Colorectal Cancer Awareness Month- a time to raise awareness for colorectal cancer and the importance of routine, life-saving screenings. Renown invites the community to join the organization in helping put an end to the preventable disease.  Blue is the designated color to bring awareness to colorectal cancer and those impacted by it. The iconic “LOVE” sculpture at the main entrance of Renown Regional Medical Center located at 1155 Mill Street in Reno, Nev. will shine brightly in blue each evening in March, serving as a visual reminder to passersby to schedule a colorectal screening. The Colorectal Cancer Alliance estimates 149,500 new cases of colon cancer will present in 2021 alone. While colorectal cancer may be the second deadliest cancer in men and women combined, it is also one of the most preventable cancers with screenings.  “Unfortunately, due to the COVID-19 pandemic, there’s been a decline in colorectal screenings nationwide,” said Tony Slonim, MD, DrPH, President and CEO of Renown Health. “We know early detection is key in preventing the spread of any cancer, and with regular screenings, we know colorectal cancer is easily detectable and treatable. As a cancer survivor, I know how important it is to get back on track with regular screenings and preventive care. Making your health a priority now will help you experience a healthier and brighter tomorrow.”   “We invite the community to join us at Renown in spreading awareness about colorectal cancer and its prevention,” said Susan Cox, director of cancer services at the Renown Institute for Cancer. “It takes all of us to put an end to colorectal cancer. If you’re up to date on your screenings, remind a loved one to schedule their next screening--as your reminder may have the power to save their life.” “Colorectal cancer usually forms from precancerous polyps, or abnormal growths, in the colon or rectum, which can become malignant without presenting any symptoms. Screening tests like stool tests, colonoscopies, and others can detect these precancerous polyps, so they can be removed by a physician before turning into cancer. Screening tests can also find colorectal cancer early, resulting in better treatment outcomes,” says Christos Galanopoulos, M.D., MBA, oncologic surgeon, VP Renown Health & Chair of Surgery for Renown Health.   Dr. Galanopoulos adds, “Most people begin screening for colorectal cancer after turning 50. However, some individuals may begin screenings earlier if they have an increased risk of colorectal cancer, such as a family history with the disease. Regardless of one’s personal or family history of colorectal cancer, it’s important to talk to your doctor about the right time to begin your screenings.”  Max J. Coppes, MD, Cancer Center Director, Renown Institute for Cancer adds, “While routine screenings are the only way to determine colorectal health, some healthy habits may reduce your risk for colorectal cancer. These factors include maintaining a healthy weight, being physically active, eating a diet rich in fresh fruits, vegetables and whole grains, limiting alcohol intake and not smoking.”  Dr. Coppes explains that, “1 in 500 Americans will test positive for Lynch Syndrome, a genetic condition that raises your risk of colon cancer, endometrial cancer, and other cancers. It is also known as hereditary nonpolyposis colorectal cancer. People with Lynch Syndrome are also susceptible to colon polyps at a younger age. The Healthy Nevada Project research team is looking at the occurrence of important inherited genetic variants in our population that increase the risk of certain diseases. These include Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome.” To enroll in The Healthy Nevada Project, a clinical study (saliva test) offering the opportunity to learn about your ancestry, diet insights and genetic risks linked to heart disease and certain cancers, including prevention strategies, at no cost, enroll here. For a limited time, Nevada residents may request a free DNA test kit that will be shipped to your home.  Renown experts encourage every adult to talk to their doctor about their colorectal cancer risk and screening options. Those looking to schedule a screening or establish care with a Renown primary care provider are invited to call us at 775-691-7308 or visit our website for more information.     About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath and Neurosciences. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.

    Read More About Awareness Saves Lives: Renown Goes Blue for Colorectal Cancer Awareness Month

Number of results found: 13
Use this additional navigation to go to the next pages. Use tab and enter keyboard keys to navigate the menu 1 Page # 2 Navigate to next page Page 1 of 2
Skipped to 13 results found. Page 1 of 2